152 related articles for article (PubMed ID: 33845738)
1. Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular Carcinoma: An Overview.
Estevinho MM; Fernandes C; Silva JC; Gomes AC; Afecto E; Correia J; Carvalho J
Curr Drug Targets; 2022; 23(1):21-32. PubMed ID: 33845738
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
Ceballos MP; Angel A; Delprato CB; Livore VI; Ferretti AC; Lucci A; Comanzo CG; Alvarez ML; Quiroga AD; Mottino AD; Carrillo MC
Eur J Pharmacol; 2021 Feb; 892():173736. PubMed ID: 33220273
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps.
Di Giacomo S; Briz O; Monte MJ; Sanchez-Vicente L; Abete L; Lozano E; Mazzanti G; Di Sotto A; Marin JJG
Arch Toxicol; 2019 Mar; 93(3):623-634. PubMed ID: 30659321
[TBL] [Abstract][Full Text] [Related]
4. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.
Borel F; Han R; Visser A; Petry H; van Deventer SJ; Jansen PL; Konstantinova P;
Hepatology; 2012 Mar; 55(3):821-32. PubMed ID: 21932399
[TBL] [Abstract][Full Text] [Related]
5. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
[TBL] [Abstract][Full Text] [Related]
6. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z
Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694
[TBL] [Abstract][Full Text] [Related]
7. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
[TBL] [Abstract][Full Text] [Related]
8. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma.
Ceballos MP; Rigalli JP; Ceré LI; Semeniuk M; Catania VA; Ruiz ML
Curr Med Chem; 2019; 26(7):1224-1250. PubMed ID: 29303075
[TBL] [Abstract][Full Text] [Related]
9. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
10. Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines.
Cuestas ML; Sosnik A; Mathet VL
Mol Pharm; 2011 Aug; 8(4):1152-64. PubMed ID: 21591727
[TBL] [Abstract][Full Text] [Related]
11. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
12. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
15. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
16. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance.
Tang M; Huang Y; Liang X; Tao Y; He N; Li Z; Guo J; Gui S
AAPS PharmSciTech; 2022 Apr; 23(5):130. PubMed ID: 35487999
[TBL] [Abstract][Full Text] [Related]
18. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW
PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
20. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]